INGN
Inogen, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.42
−0.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 354.3M | 348.7M | 335.7M | 315.7M | 377.2M |
| Cost of Revenue | 181.1M | 182.8M | 181.0M | 189.0M | 223.7M |
| Gross Profit | 173.2M | 165.9M | 154.7M | 126.7M | 153.5M |
| Operating Expenses | |||||
| R&D Expense | 21.1M | 19.4M | 21.6M | 20.8M | 21.9M |
| SG&A Expense | 167.4M | 165.1M | 175.6M | 182.4M | 164.7M |
| General & Admin Expense | 69.4M | 67.4M | 72.6M | 75.3M | 43.9M |
| Selling & Marketing Expense | 98.0M | 97.7M | 103.1M | 107.1M | 120.8M |
| Other Expenses | 14.6M | 11.6M | — | 32.9M | 52.2M |
| Total Operating Expenses | 203.2M | 196.1M | 197.3M | 236.1M | 238.8M |
| Cost and Expenses | 384.2M | 378.9M | 378.2M | 425.0M | 462.5M |
| Operating Income (EBIT) | (29.9M) | (30.2M) | (42.5M) | (109.4M) | (85.2M) |
| Non-Operating | |||||
| Interest Income | 3.9M | 2.2M | 5.2M | 6.6M | 2.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 3.9M | 2.2M | 5.2M | 6.6M | 2.8M |
| Other Non-Op Income/Expense | 4.6M | 6.8M | 6.0M | 7.0M | 2.0M |
| Non-Operating Income (excl Interest) | (4.6M) | (6.8M) | (6.0M) | (32.9M) | (52.2M) |
| EBT (Pre-Tax Income) | (25.3M) | (23.4M) | (36.5M) | (102.3M) | (83.3M) |
| Income Tax Expense | (710.0K) | (632.0K) | (588.0K) | 105.0K | 504.0K |
| Bottom Line | |||||
| Net Income | (24.6M) | (22.7M) | (35.9M) | (102.4M) | (83.8M) |
| Earnings from Cont. Ops | (24.6M) | (22.7M) | (35.9M) | (102.4M) | (83.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.6M) | (22.7M) | (35.9M) | (102.4M) | (83.8M) |
| Per Share | |||||
| Basic EPS | ($0.90) | ($0.85) | ($1.52) | ($4.42) | ($3.67) |
| Diluted EPS | ($0.90) | ($0.85) | ($1.52) | ($4.42) | ($3.67) |
| Revenue Per Share | $13.10 | $12.83 | $14.19 | $13.62 | $16.51 |
| Shares | |||||
| Basic Shares Outstanding | 27.0M | 27.2M | 23.7M | 23.2M | 22.9M |
| Diluted Shares Outstanding | 27.0M | 27.2M | 23.7M | 23.2M | 22.9M |
| Profitability Metrics | |||||
| EBITDA | (6.7M) | (2.7M) | (15.5M) | (58.3M) | (9.6M) |
| D&A | 18.6M | 20.7M | 21.0M | 18.2M | 23.5M |
| EBIT | (25.3M) | (23.4M) | (36.5M) | (76.5M) | (33.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026